OPKO Health (OPK) Expected to Announce Earnings on Thursday

OPKO Health (NASDAQ:OPK - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $155.42 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

OPKO Health Stock Up 0.6 %

Shares of OPK stock traded up $0.01 during trading hours on Friday, reaching $1.68. 2,628,589 shares of the company's stock were exchanged, compared to its average volume of 2,774,708. The stock's 50 day moving average is $1.54 and its 200-day moving average is $1.54. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -8.84 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $1.56 per share, with a total value of $780,000.00. Following the purchase, the chief executive officer now directly owns 212,411,477 shares in the company, valued at $331,361,904.12. The trade was a 0.24 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have purchased 1,521,609 shares of company stock valued at $2,313,710. Company insiders own 47.26% of the company's stock.

Wall Street Analyst Weigh In

OPK has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, January 8th. StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a research report on Wednesday, January 15th. Finally, Barrington Research reissued an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.